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The huge diffusion of hypertension and its 
associated complications has a significant impact on 
public health [1]. However, despite the high prevalence 
of essential hypertension and many efforts of research, 
the basic pathophysiological causes remain puzzling. 
Although in the simplest way, the determinants of 
blood pressure (BP) are approximated by physical laws 
for fluid dynamics, these components of BP and their 
interactions have been intensely examined for years, 
without untangling the core of the problem. A more recent 
field of studies in hypertension has begun to shed light 
on a previously unpredictable role of the immune system 
in regulating BP [2]. Nevertheless, even though it is now 
recognized that T cell response drives hypertension, the 
key immune pathways contributing to BP elevation are 
still unidentified.
Our recent work outlined an unprecedented role 
of immune system in the spleen, orchestrating the 
response of T cell to hypertensive challenge, through 
the angiogenic factor named Placental Growth Factor 
(PlGF) [3]. Two main points emerge in our study. 
First, the finding that PlGF-deficient mice manifest 
protection from AngII-induced hypertension, one of the 
most common experimental models of hypertension. 
Second, our work highlighted an unprecedented and 
unexpected role of the splenic neuroimmune interaction 
in hypertension. Although the fact that T cells are 
recruited in the vasculature during hypertension has 
been well documented, how and where they are activated 
was still unclear. In our paper, we have defined that the 
spleen is crucial in the onset of hypertension, given that 
splenectomized mice are protected from the blood pressure 
raising typically occurring upon chronic infusion of AngII. 
Moreover, the sympathetic drive converging in the spleen 
and departing from the celiac ganglion is necessary for the 
induction of PlGF in the MZ of splenic reservoir upon the 
AngII hypertensive challenge. Thus, we started to think 
about a “neuroimmune” pathway mediated by PlGF and 
necessary for the onset of hypertension. The generation 
of chimeric mice, obtained by spleen transplantation and 
harboring a PlGF-deficient spleen in a WT background and 
the contrary, allowed us to finally demonstrate that PlGF 
is needed in the spleen to allow the activation of T cells 
and blood pressure raising. Once activated in the spleen, 
PlGF is crucial to allow T cell costimulation via CD86 
and their consequent egress for the deployment toward 
vasculature of target organs, a hallmark of hypertension. 
The identification of an epigenetic modulation, responsible 
for the PlGF-mediated mechanism of T cells co-
stimulation, highlights intriguing questions that range over 
cardiology toward oncology. In particular, we found that 
the co-stimulatory molecule CD86 is regulated by Timp3 
expression, depending in turn on the activity of Sirt1 
deacetylase activity on p53 repressor activity. 
Despite the unquestionable basic research 
implications that our results would have in the ever-
growing field of studies on immune system and 
hypertension, what is more important is the opportunity 
arousing in terms of therapeutic potential. Indeed, the 
possibility to use potent immunosuppressive agents 
to treat uncomplicated hypertension would inevitably 
provoke some uncertainty. On the other hand, with the 
identification of key immune pathways contributing to 
BP elevation, specific therapeutic interventions might 
be devised to ameliorate hypertension, minimizing the 
potential immunosuppressive deleterious effects. On this 
issue, PlGF appears as an appealing molecular target for 
therapeutic implications, since tools clinically affording 
this pathway already exist [4, 5]. In the last years, anti-
PlGF monoclonal antibodies have been developed as 
a strategy to slow tumor growth and for age-related 
macular degeneration. The ongoing clinical trials, testing 
humanized monoclonal antibodies directed to PlGF, 
encourage the possibility to endeavor this way also in 
hypertension and hopefully fulfill the pressing priority 
to reach satisfactory control rates in the substantial 
proportion of people with hypertension that, although 
under treatment, do not achieve the BP target levels 
recommended by current guideline. 
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At same time, our findings encourage a reflection 
about the possibility that some of the effects so far 
attributed to PlGF inhibition in cancer may rely on the 
previously unknown capability to exert an epigenetic 
modulation of p53-Timp3 axis, which is well known to 
play a crucial role also in tumor growth. Further studies 
directed at this issue, could help to explain how a single 
molecule like PlGF could play so wide and, at same time 
similar, effects in different pathophysiological context, 
like hypertension and cancer.
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